A detailed history of Bill Few Associates, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bill Few Associates, Inc. holds 3,954 shares of GILD stock, worth $365,389. This represents 0.12% of its overall portfolio holdings.

Number of Shares
3,954
Previous 3,720 6.29%
Holding current value
$365,389
Previous $255,000 29.8%
% of portfolio
0.12%
Previous 0.1%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$66.59 - $83.99 $15,582 - $19,653
234 Added 6.29%
3,954 $331,000
Q2 2024

Jul 16, 2024

BUY
$63.15 - $72.88 $31,575 - $36,440
500 Added 15.53%
3,720 $255,000
Q1 2024

Apr 18, 2024

BUY
$71.58 - $87.29 $22,547 - $27,496
315 Added 10.84%
3,220 $235,000
Q4 2023

Jan 16, 2024

SELL
$73.27 - $83.09 $36,635 - $41,545
-500 Reduced 14.68%
2,905 $235,000
Q3 2023

Oct 20, 2023

BUY
$73.94 - $80.67 $251,765 - $274,681
3,405 New
3,405 $255,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Bill Few Associates, Inc. Portfolio

Follow Bill Few Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bill Few Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bill Few Associates, Inc. with notifications on news.